| Magalang, Ulysses |
| Active, not recruiting | N/A | 900 | US | aerSleep II | Sommetrics, Inc. | Sleep Apnea, Obstructive, Apnea, Sleep | 12/25 | 12/25 | | |
| Brothers, Trish |
NCT03727880: Study of Pembrolizumab With or Without Defactinib Following Chemotherapy as a Neoadjuvant and Adjuvant Treatment for Resectable Pancreatic Ductal Adenocarcinoma |
|
|
| Recruiting | 2 | 36 | US | Pembrolizumab, MK-3475, Keytruda, Defactinib | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Merck Sharp & Dohme LLC, Verastem, Inc. | Resectable Pancreatic Ductal Adenocarcinoma (PDAC), Pancreatic Ductal Adenocarcinoma | 12/24 | 12/24 | | |
NCT03638141: CTLA-4 /PD-L1 Blockade Following Transarterial Chemoembolization (DEB-TACE) in Patients With Intermediate Stage of HCC (Hepatocellular Carcinoma) Using Durvalumab and Tremelimumab |
|
|
| Completed | 2 | 21 | US | Durvalumab, MEDI4736, Tremelimumab (Cohort A dose), CP-675,206, Tremelimumab (Cohort B dose) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, AstraZeneca | Intermediate Stage of Hepatocellular Carcinoma, Hepatocellular Carcinoma | 08/24 | 08/24 | | |
NCT03642067: Study of Nivolumab and Relatlimab in Patients With Microsatellite Stable (MSS) Advanced Colorectal Cancer |
|
|
| Completed | 2 | 59 | US | Nivolumab, OPDIVO, BMS-936558, anti-PD-1, Relatlimab, BMS-986016, anti-LAG-3 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Bristol-Myers Squibb | Microsatellite Stable (MSS) Colorectal Adenocarcinomas, Colorectal Adenocarcinoma | 02/24 | 09/24 | | |
NCT04209686: Paclitaxel, Pembrolizumab and Olaparib in Previously Treated Advanced Gastric Adenocarcinoma |
|
|
| Recruiting | 2 | 36 | US | Paclitaxel, Taxol, Olaparib, Lynparza, Pembrolizumab, MK-3475; Keytruda | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Merck Sharp & Dohme LLC | Advanced Gastric Adenocarcinoma | 04/28 | 04/28 | | |
NCT03607890: Study of Nivolumab and Relatlimab in Advanced Mismatch Repair Deficient Cancers Resistant to Prior PD-(L)1 Inhibitor |
|
|
| Recruiting | 2 | 42 | US | Nivolumab, anti-PD-1, OPDIVO, Relatlimab, BMS-986016 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Bristol-Myers Squibb, National Cancer Institute (NCI) | Refractory MSI - H Solid Tumors Prior of PD-(L) 1 Therapy, MSI-H Tumors | 10/25 | 10/25 | | |
CA209-8DP, NCT03521830: Nivolumab Alone or Plus Relatlimab or Ipilimumab for Patients With Locally-Advanced Unresectable or Metastatic Basal Cell Carcinoma |
|
|
| Recruiting | 2 | 57 | US | Nivolumab, Opdivo, Ipilimumab, Yervoy, Relatlimab | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Bristol-Myers Squibb | Basal Cell Carcinoma | 03/26 | 03/27 | | |
NCT04116073: INCMGA00012 in Patients With Previously Treated Unresectable or Metastatic Adenosquamous Pancreatic or Ampullary Cancer |
|
|
| Completed | 2 | 25 | US | INCMGA00012 (PD-1 antibody), MGA012 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Incyte Corporation, National Cancer Institute (NCI) | Pancreatic Cancer Non-resectable, Pancreatic Cancer Metastatic | 08/24 | 12/24 | | |
NCT04753879: Multi-agent Low Dose Chemotherapy GAX-CI Followed by Olaparib and Pembro in Metastatic Pancreatic Ductal Cancer. |
|
|
| Recruiting | 2 | 38 | US | Nab-paclitaxel, Gemcitabine, Cisplatin, Irinotecan, Capecitabine, Pembrolizumab, Olaparib | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Merck Sharp & Dohme LLC | Metastatic Pancreatic Cancer | 12/25 | 12/29 | | |
NCT05604560: A Neoadjuvant Study of Tislelizumab and SX-682 for Resectable Pancreas Cancer |
|
|
| Recruiting | 2 | 25 | US | Tislelizumab, BGB-A317, SX-682 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, BeiGene, Syntrix Biosystems, Inc. | Pancreatic Cancer | 09/26 | 09/26 | | |
NCT03767582: Trial of Neoadjuvant and Adjuvant Nivolumab and BMS-813160 With or Without GVAX for Locally Advanced Pancreatic Ductal Adenocarcinomas. |
|
|
| Completed | 1/2 | 46 | US | Stereotactic Body Radiation (SBRT), Nivolumab, OPDIVO, CCR2/CCR5 dual antagonist, BMS-813160, GVAX, PANC 10.05 pcDNA-1/GM-Neo vaccine, PANC 6.03 pcDNA-1/GM-Neo vaccine | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Bristol-Myers Squibb | Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC), Pancreatic Ductal Adenocarcinoma | 09/24 | 09/24 | | |
NCT04799431: Neoantigen-Targeted Vaccine Combined With Anti-PD-1 Antibody for Patients With Stage IV MMR-p Colon and Pancreatic Ductal Cancer |
|
|
| Withdrawn | 1 | 12 | NA | Neoantigen Vaccine with Poly-ICLC adjuvant, Hiltonol® (Poly-ICLC), Retifanlimab, INCMGA00012; MGA012 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Incyte Corporation, National Cancer Institute (NCI) | Pancreatic Cancer Metastatic, Colorectal Cancer Metastatic | 05/23 | 05/23 | | |
IRB00210915, NCT04117087: Pooled Mutant KRAS-Targeted Long Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Resected Mismatch Repair Protein (MMR-p) Colorectal and Pancreatic Cancer |
|
|
| Recruiting | 1 | 30 | US | KRAS peptide vaccine, Hiltonol® (Poly-ICLC), Nivolumab, OPDIVO, Ipilimumab, YERVOY® | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Bristol-Myers Squibb, National Cancer Institute (NCI), National Institutes of Health (NIH) | Colorectal Cancer, Pancreatic Cancer | 08/25 | 08/25 | | |
NCT04658147: Feasibility and Efficacy of Perioperative Nivolumab With or Without Relatlimab for Patients With Potentially Resectable Hepatocellular Carcinoma (HCC) |
|
|
| Recruiting | 1 | 20 | US | Nivolumab, OPDIVO™, BMS 936558, MDX1106, ONO-4538, Relatlimab, BMS-986016, BMS-986016-01, Anti-LAG-3 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Bristol-Myers Squibb | Hepatocellular Carcinoma | 06/25 | 06/26 | | |
